BioCentury
ARTICLE | Clinical News

AVI BioPharma starts Phase II with Resten-NG

June 28, 2000 7:00 AM UTC

AVII started a 120-patient U.S. Phase II trial of Resten-NG antisense compound to treat cardiovascular restenosis following angioplasty. Resten-NG was developed with AVII's NeuGene antisense technolog...